A Novel, Non-Invasive and Therapeutically Useful High Throughput Technique to Isolate Highly Enriched Tumor Reactive Lymphocytes from Peripheral Blood - Potential Use in Adoptive Immunotherapy
Description of Invention:
The adoptive transfer of autologous antigen reactive lymphocytes has been shown to mediate significant tumor regression in some patients with metastatic cancer. However, the isolation of these T lymphocytes requires invasive surgery, which can lead to post-operative complications and delays in initiating adoptive immunotherapy with T cells.
This technology is directed to the use of a novel high throughput technique to isolate highly enriched tumor reactive lymphocytes in a non-invasive manner from the peripheral blood of cancer patients for the purpose of cancer immunotherapy. The technique utilizes a highly sensitive PCR based screening assay.
Applications:
The isolated T lymphocytes can be used in adoptive immunotherapy for the treatment of metastatic cancer.
Advantages:
A rapid and non-invasive high throughput method of isolating tumor reactive T cells, which is otherwise difficult with conventional peripheral blood isolating techniques.
The method is easy to use and based on a highly sensitive PCR based screening assay.
The method can detect the presence of extremely rare T cells in a bulk population of peripheral blood cells.
Development Status:
The method of isolating tumor reactive T lymphocytes has been established. The method was successfully used to isolate tumor reactive T cells from peripheral blood of cancer patients.
Patent Status:
DHHS Reference No. E-003-2008/0 --
U.S. Patent Application No. 61/027,623 filed 11 Feb 2008
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this high throughput T cell isolation technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Devices/Instrumentation Cancer
Cancer -Therapeutics-Immunomodulators and Immunostimulants Cancer -Therapeutics Devices/Instrumentation-Therapeutics
For Additional Information Please Contact: Sabarni K. Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5587
Email: chatterjeesa@mail.nih.gov
Fax: 301/402-0220
